nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—VIIth nerve paralysis—Riluzole—amyotrophic lateral sclerosis	0.0436	0.076	CcSEcCtD
Methyldopa—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.0413	0.0721	CcSEcCtD
Methyldopa—DDC—nerve—amyotrophic lateral sclerosis	0.0353	0.186	CbGeAlD
Methyldopa—DDC—hindbrain—amyotrophic lateral sclerosis	0.0265	0.14	CbGeAlD
Methyldopa—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.0216	0.0376	CcSEcCtD
Methyldopa—DDC—Biogenic Amine Synthesis—CHAT—amyotrophic lateral sclerosis	0.0215	0.0914	CbGpPWpGaD
Methyldopa—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.0212	0.037	CcSEcCtD
Methyldopa—DDC—Parkinsons Disease Pathway—ATXN2—amyotrophic lateral sclerosis	0.0209	0.089	CbGpPWpGaD
Methyldopa—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.0203	0.0355	CcSEcCtD
Methyldopa—COMT—Biogenic Amine Synthesis—CHAT—amyotrophic lateral sclerosis	0.0191	0.0812	CbGpPWpGaD
Methyldopa—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.0179	0.0312	CcSEcCtD
Methyldopa—DDC—embryo—amyotrophic lateral sclerosis	0.0165	0.0873	CbGeAlD
Methyldopa—ADRA2A—peripheral nervous system—amyotrophic lateral sclerosis	0.0153	0.0805	CbGeAlD
Methyldopa—DDC—brainstem—amyotrophic lateral sclerosis	0.0152	0.08	CbGeAlD
Methyldopa—Eczema—Riluzole—amyotrophic lateral sclerosis	0.0144	0.0252	CcSEcCtD
Methyldopa—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.0143	0.025	CcSEcCtD
Methyldopa—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.014	0.0244	CcSEcCtD
Methyldopa—DDC—Dopamine metabolism—SOD1—amyotrophic lateral sclerosis	0.0133	0.0564	CbGpPWpGaD
Methyldopa—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.0129	0.0225	CcSEcCtD
Methyldopa—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.0127	0.0221	CcSEcCtD
Methyldopa—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.012	0.0209	CcSEcCtD
Methyldopa—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.0119	0.0207	CcSEcCtD
Methyldopa—COMT—Dopamine metabolism—SOD1—amyotrophic lateral sclerosis	0.0118	0.0501	CbGpPWpGaD
Methyldopa—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.0117	0.0205	CcSEcCtD
Methyldopa—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.0113	0.0197	CcSEcCtD
Methyldopa—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.011	0.0192	CcSEcCtD
Methyldopa—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.0109	0.0191	CcSEcCtD
Methyldopa—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.0107	0.0186	CcSEcCtD
Methyldopa—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.0103	0.018	CcSEcCtD
Methyldopa—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.0102	0.0178	CcSEcCtD
Methyldopa—COMT—brainstem—amyotrophic lateral sclerosis	0.01	0.0529	CbGeAlD
Methyldopa—Infestation—Riluzole—amyotrophic lateral sclerosis	0.01	0.0174	CcSEcCtD
Methyldopa—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.01	0.0174	CcSEcCtD
Methyldopa—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00975	0.017	CcSEcCtD
Methyldopa—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00946	0.0165	CcSEcCtD
Methyldopa—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00933	0.0163	CcSEcCtD
Methyldopa—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00914	0.0159	CcSEcCtD
Methyldopa—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00898	0.0157	CcSEcCtD
Methyldopa—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00882	0.0154	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00858	0.0364	CbGpPWpGaD
Methyldopa—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00833	0.0145	CcSEcCtD
Methyldopa—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00815	0.0142	CcSEcCtD
Methyldopa—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00809	0.0141	CcSEcCtD
Methyldopa—DDC—nervous system—amyotrophic lateral sclerosis	0.00795	0.0419	CbGeAlD
Methyldopa—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00787	0.0137	CcSEcCtD
Methyldopa—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.0077	0.0134	CcSEcCtD
Methyldopa—DDC—central nervous system—amyotrophic lateral sclerosis	0.00765	0.0404	CbGeAlD
Methyldopa—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC1A2—amyotrophic lateral sclerosis	0.00709	0.0301	CbGpPWpGaD
Methyldopa—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.007	0.0122	CcSEcCtD
Methyldopa—COMT—medulla oblongata—amyotrophic lateral sclerosis	0.00699	0.0369	CbGeAlD
Methyldopa—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00665	0.0116	CcSEcCtD
Methyldopa—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00665	0.0116	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00661	0.0115	CcSEcCtD
Methyldopa—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00638	0.0111	CcSEcCtD
Methyldopa—Infection—Riluzole—amyotrophic lateral sclerosis	0.00634	0.0111	CcSEcCtD
Methyldopa—DDC—Parkinsons Disease Pathway—CASP9—amyotrophic lateral sclerosis	0.00628	0.0267	CbGpPWpGaD
Methyldopa—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00626	0.0109	CcSEcCtD
Methyldopa—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00625	0.0109	CcSEcCtD
Methyldopa—COMT—spinal cord—amyotrophic lateral sclerosis	0.00624	0.0329	CbGeAlD
Methyldopa—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.0062	0.0108	CcSEcCtD
Methyldopa—DDC—brain—amyotrophic lateral sclerosis	0.00607	0.0321	CbGeAlD
Methyldopa—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC1A3—amyotrophic lateral sclerosis	0.00602	0.0256	CbGpPWpGaD
Methyldopa—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00581	0.0101	CcSEcCtD
Methyldopa—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00573	0.00999	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00551	0.0096	CcSEcCtD
Methyldopa—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00545	0.00951	CcSEcCtD
Methyldopa—COMT—nervous system—amyotrophic lateral sclerosis	0.00525	0.0277	CbGeAlD
Methyldopa—DDC—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.00513	0.0218	CbGpPWpGaD
Methyldopa—COMT—central nervous system—amyotrophic lateral sclerosis	0.00506	0.0267	CbGeAlD
Methyldopa—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00504	0.00879	CcSEcCtD
Methyldopa—DDC—Amino acid and derivative metabolism—DAO—amyotrophic lateral sclerosis	0.00496	0.0211	CbGpPWpGaD
Methyldopa—COMT—cerebellum—amyotrophic lateral sclerosis	0.00494	0.0261	CbGeAlD
Methyldopa—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.0047	0.00819	CcSEcCtD
Methyldopa—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00458	0.00798	CcSEcCtD
Methyldopa—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00436	0.00761	CcSEcCtD
Methyldopa—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00422	0.00736	CcSEcCtD
Methyldopa—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC1A2—amyotrophic lateral sclerosis	0.00417	0.0177	CbGpPWpGaD
Methyldopa—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00406	0.00707	CcSEcCtD
Methyldopa—Rash—Riluzole—amyotrophic lateral sclerosis	0.00402	0.00701	CcSEcCtD
Methyldopa—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00402	0.00701	CcSEcCtD
Methyldopa—COMT—brain—amyotrophic lateral sclerosis	0.00402	0.0212	CbGeAlD
Methyldopa—Headache—Riluzole—amyotrophic lateral sclerosis	0.004	0.00697	CcSEcCtD
Methyldopa—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00379	0.00661	CcSEcCtD
Methyldopa—ADRA2A—medulla oblongata—amyotrophic lateral sclerosis	0.00356	0.0188	CbGeAlD
Methyldopa—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC1A3—amyotrophic lateral sclerosis	0.00355	0.0151	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.00331	0.014	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.00331	0.014	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.00331	0.014	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00326	0.0138	CbGpPWpGaD
Methyldopa—ADRA2A—spinal cord—amyotrophic lateral sclerosis	0.00318	0.0168	CbGeAlD
Methyldopa—COMT—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00317	0.0135	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.00293	0.0124	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.00283	0.012	CbGpPWpGaD
Methyldopa—ADRA2A—nervous system—amyotrophic lateral sclerosis	0.00268	0.0141	CbGeAlD
Methyldopa—DDC—Parkinsons Disease Pathway—CASP3—amyotrophic lateral sclerosis	0.00264	0.0112	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.00259	0.011	CbGpPWpGaD
Methyldopa—ADRA2A—central nervous system—amyotrophic lateral sclerosis	0.00258	0.0136	CbGeAlD
Methyldopa—ADRA2A—cerebellum—amyotrophic lateral sclerosis	0.00252	0.0133	CbGeAlD
Methyldopa—COMT—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.00249	0.0106	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00243	0.0103	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.00241	0.0102	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.00241	0.0102	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.00228	0.00968	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00224	0.00953	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00217	0.00921	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.00214	0.00911	CbGpPWpGaD
Methyldopa—ADRA2A—brain—amyotrophic lateral sclerosis	0.00205	0.0108	CbGeAlD
Methyldopa—COMT—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00198	0.00842	CbGpPWpGaD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00186	0.00792	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00184	0.00783	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00184	0.00783	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.00171	0.00726	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00164	0.00698	CbGpPWpGaD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.00159	0.00673	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00147	0.00625	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.00146	0.0062	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.00144	0.00611	CbGpPWpGaD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.00141	0.006	CbGpPWpGaD
Methyldopa—DDC—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00126	0.00535	CbGpPWpGaD
Methyldopa—DDC—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00126	0.00535	CbGpPWpGaD
Methyldopa—DDC—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00115	0.00489	CbGpPWpGaD
Methyldopa—COMT—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00112	0.00475	CbGpPWpGaD
Methyldopa—COMT—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00112	0.00475	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.00112	0.00474	CbGpPWpGaD
Methyldopa—DDC—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00107	0.00455	CbGpPWpGaD
Methyldopa—COMT—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00102	0.00434	CbGpPWpGaD
Methyldopa—DDC—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00101	0.00428	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.00101	0.00427	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00095	0.00404	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000947	0.00402	CbGpPWpGaD
Methyldopa—Aminosalicylic Acid—PTGS2—amyotrophic lateral sclerosis	0.000932	0.56	CrCbGaD
Methyldopa—DDC—Metabolism—DAO—amyotrophic lateral sclerosis	0.00091	0.00387	CbGpPWpGaD
Methyldopa—COMT—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000894	0.0038	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000854	0.00363	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.00084	0.00357	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.00083	0.00353	CbGpPWpGaD
Methyldopa—COMT—Metabolism—DAO—amyotrophic lateral sclerosis	0.000808	0.00343	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000806	0.00342	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000806	0.00342	CbGpPWpGaD
Methyldopa—Mesalazine—PTGS2—amyotrophic lateral sclerosis	0.000731	0.44	CrCbGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000725	0.00308	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000718	0.00305	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00069	0.00293	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000668	0.00284	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSR—amyotrophic lateral sclerosis	0.000637	0.0027	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000612	0.0026	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000576	0.00245	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSR—amyotrophic lateral sclerosis	0.000565	0.0024	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000535	0.00227	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000523	0.00222	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000518	0.0022	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000509	0.00216	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000486	0.00206	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000464	0.00197	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000447	0.0019	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000444	0.00189	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000444	0.00189	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000436	0.00185	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000406	0.00173	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000378	0.0016	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000367	0.00156	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000355	0.00151	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—DAO—amyotrophic lateral sclerosis	0.000321	0.00136	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	0.000296	0.00126	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000292	0.00124	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000288	0.00122	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000281	0.00119	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000261	0.00111	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000258	0.0011	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000251	0.00106	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000249	0.00106	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000243	0.00103	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000229	0.000974	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000225	0.000955	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSR—amyotrophic lateral sclerosis	0.000225	0.000954	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000222	0.000943	CbGpPWpGaD
Methyldopa—DDC—Metabolism—APOE—amyotrophic lateral sclerosis	0.000212	0.000902	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000204	0.000865	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	0.000194	0.000822	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000191	0.000813	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOE—amyotrophic lateral sclerosis	0.000189	0.000801	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000184	0.000784	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000181	0.000771	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000176	0.000746	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000156	0.000663	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000154	0.000655	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000153	0.000649	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000146	0.000618	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000129	0.000549	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000129	0.000548	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000126	0.000533	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000114	0.000484	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000106	0.00045	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—amyotrophic lateral sclerosis	9.98e-05	0.000424	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.94e-05	0.000422	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.91e-05	0.000421	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.47e-05	0.000402	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.11e-05	0.000387	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.1e-05	0.000344	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.62e-05	0.000324	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—amyotrophic lateral sclerosis	7.54e-05	0.00032	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOE—amyotrophic lateral sclerosis	7.5e-05	0.000318	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.73e-05	0.000286	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.27e-05	0.000266	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.18e-05	0.00022	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.14e-05	0.000218	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.99e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.77e-05	0.00016	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.38e-05	0.000144	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.56e-05	0.000109	CbGpPWpGaD
